DrugPatentWatch Database Preview

Details for Patent: 8,338,427

« Back to Dashboard

Which drugs does patent 8,338,427 protect, and when does it expire?

Patent 8,338,427 protects ABILIFY MAINTENA KIT and is included in one NDA.

This patent has twenty-four patent family members in twenty countries.

Summary for Patent: 8,338,427

Title:	Methods for administering aripiprazole
Abstract:	The present invention relates, in part, to the discovery that a pharmaceutical composition comprising aripiprazole and a carrier administered in a bolus injection resulted in an extended release profile similar to that obtained by the injection of a poly lactide-co-glycolide microsphere formulation containing the active agent. This surprising result suggests that pharmacologically beneficial extended release formulations without the complexities and expense associated with the manufacture microspheres.
Inventor(s):	Brown; Josiah (Seattle, WA)
Assignee:	Alkermes, Inc. (Waltham, MA)
Application Number:	12/251,656
Patent Claim Types: see list of patent claims	Composition; Use;

Drugs Protected by US Patent 8,338,427

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Otsuka Pharm Co Ltd	ABILIFY MAINTENA KIT	aripiprazole	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	202971-001	Feb 28, 2013		RX	Yes	No			Y			TREATMENT OF SCHIZOPHRENIA
Otsuka Pharm Co Ltd	ABILIFY MAINTENA KIT	aripiprazole	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	202971-001	Feb 28, 2013		RX	Yes	No			Y			USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
Otsuka Pharm Co Ltd	ABILIFY MAINTENA KIT	aripiprazole	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	202971-003	Sep 29, 2014		RX	Yes	No			Y			USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
Otsuka Pharm Co Ltd	ABILIFY MAINTENA KIT	aripiprazole	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	202971-003	Sep 29, 2014		RX	Yes	No			Y			TREATMENT OF SCHIZOPHRENIA

Non-Orange Book US Patents Family Members for Patent 8,338,427

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
8,338,428	Methods for administering aripiprazole
8,759,351	Methods for administering aripiprazole

International Patents Family Members for US Patent 8,338,427

Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	522200
Australia	2004264886
Canada	2534997
China	102133171